Premium
Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients
Author(s) -
EBARA MASAAKI,
OHTO MASAO,
SUGIURA NOBUYUKI,
KITA KAZUHIKO,
YOSHIKAWA MASAHARU,
OKUDA KUNIO,
KONDO FUKUO,
KONDO YOICHIRO
Publication year - 1990
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.1990.tb01115.x
Subject(s) - medicine , percutaneous ethanol injection , hepatocellular carcinoma , percutaneous , gastroenterology , lesion , overall survival , survival rate , survival analysis , surgery , radiofrequency ablation , ablation
Percutaneous ethanol injection (PEI) was applied to 120 lesions in 95 patients with hepatocellular carcinomas (HCC) smaller than 3 cm in the past 6 years. All main target tumours, in 67 patients who had been followed by sonography for more than 6 months after PEI, decreased in size; 28 tumours (41.8%) became undetectable and have remained so until now. The 1‐, 2‐, 3‐, 4‐ and 5‐year survival rates calculated by the Kaplan‐Meier method were 93%, 81%, 65%, 52% and 28% respectively. These survival rates were better than those of patients with HCC smaller than 3 cm who did not receive anticancer treatment ( P <0.01). The survival of patients of the Child's A or Child's B status was better than that of those with Child's C disease. Recurrence occurred in areas within the liver different from the original lesion in 34% in one year, 61% in two years and 66% in three years after PEI. PEI was then repeated in 61% of such patients.